Pancreatic Cancer Research

ResearcherKansai Medical UniversityActive in the last 2 years

Hiroyuki Ishida

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-3359-4864; OpenAlex author ID A5037848161, A5122780679, A5138201524. Sources: OpenAlex.

Their work

Papers
16 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
61
Papers, trials and grants by year

2022: 3 papers · 2023: 1 paper · 2024: none · 2025: 3 papers · 2026: 9 papers

Papers 16

  1. Survival Impact of Pathological Residual Patterns for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy. Co-author DOI 10.1002/jhbp.70146↗
  2. Incidence and consequences of chyle leak after pancreatectomy for pancreatic cancer. Co-author DOI 10.1016/j.hpb.2025.10.004↗
  3. Patterns of treatment and survival in borderline resectable and locally advanced pancreatic cancer. Co-author DOI 10.1016/j.pan.2025.12.007↗
  4. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  5. Neurogenic diarrhoea after superior mesenteric artery divestment or resection for pancreatic adenocarcinoma following preoperative chemotherapy: international … Co-author DOI 10.1093/bjsopen/zrag057↗
  6. Impact of preoperative radiotherapy on the risk of postpancreatectomy haemorrhage and major morbidity after resection of pancreatic adenocarcinoma including ar… Co-author DOI 10.1093/bjsopen/zrag058↗
  7. Portomesenteric Venous Thrombosis After Pancreatic Cancer Surgery With Venous Resection and Reconstruction: Timing, Incidence, and Risk Factors. Co-author DOI 10.1097/sla.0000000000006605↗
  8. Neoadjuvant Therapy for Invasive Intraductal Papillary Mucinous Neoplasms: A Comparative Study With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18426-y↗
  9. ASO Visual Abstract: Neoadjuvant Therapy for Invasive Intraductal Papillary Mucinous Neoplasms: a Comparative Study with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18603-z↗
  10. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  11. Importance of increasing resection rates in pancreatic cancer treatment. First author DOI 10.1093/bjsopen/zraf029↗
  12. Surgery for Borderline Resectable and Locally Advanced Pancreatic Cancer with Arterial Encasement after Neoadjuvant Therapy: A Single-center Experience. Co-author DOI 10.1097/sla.0000000000006690↗
  13. Prognostic Value of Peritoneal Lavage Cytology in Potentially Resectable Pancreatic Cancer Stratified by Cytologic Status. Co-author DOI 10.21873/cdp.10221↗
  14. Optimal Region of Lymph Node Dissection in Distal Pancreatectomy for Left-Sided Pancreatic Cancer Based on Tumor Location. Co-author DOI 10.1245/s10434-021-11108-5↗
  15. ASO Author Reflections: Optimal Region of Lymph Node Dissection in Distal Pancreatectomy for Pancreatic Cancer Based on Tumor Location: Should We Dissect Non-P… Co-author DOI 10.1245/s10434-021-11115-6↗
  16. Importance of an appropriate number of examined lymph nodes in patients with pancreatic cancer-the more the better? First author DOI 10.21037/hbsn-22-163↗

Closest collaborators

The 25 strongest of 61 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Richard David Schulick · 9 shared papers, 2025–2026 · strength 2.52
  2. Marco Del Chiaro · 8 shared papers, 2025–2026 · strength 2.24
  3. Oskar Franklin · 8 shared papers, 2025–2026 · strength 2.10
  4. Thomas F. Stoop · 6 shared papers, 2025–2026 · strength 1.52
  5. Andrii Khomiak · 3 shared papers, 2026 · strength 0.86
  6. Amane Takahashi · 4 shared papers, 2022–2023 · strength 0.84
  7. Toshiro Ogura · 4 shared papers, 2022–2023 · strength 0.84
  8. Toshitaka Sugawara · 3 shared papers, 2026 · strength 0.75
  9. Yuki Fujiwara · 2 shared papers, 2026 · strength 0.58
  10. Yoshiyuki Kawashima · 3 shared papers, 2022–2023 · strength 0.57
  11. Asif Halimi · 2 shared papers, 2026 · strength 0.47
  12. Freek D. Daams · 2 shared papers, 2026 · strength 0.37
  13. Ingmar Florin Rompen · 2 shared papers, 2026 · strength 0.37
  14. Patrik Larsson · 2 shared papers, 2026 · strength 0.37
  15. Jennifer L. Leiting · 2 shared papers, 2026 · strength 0.37
  16. Ernesto Sparrelid · 2 shared papers, 2026 · strength 0.37
  17. Bas Groot Koerkamp · 2 shared papers, 2026 · strength 0.37
  18. Poya Ghorbani · 2 shared papers, 2026 · strength 0.37
  19. Roeland F. de Wilde · 2 shared papers, 2026 · strength 0.37
  20. Michael L. Kendrick · 2 shared papers, 2026 · strength 0.37
  21. Christopher Lee Wolfgang · 2 shared papers, 2026 · strength 0.37
  22. Marc G. Besselink · 2 shared papers, 2026 · strength 0.37
  23. Cornelius A. Thiels · 2 shared papers, 2026 · strength 0.37
  24. Mark Joseph Truty · 2 shared papers, 2026 · strength 0.37
  25. Geert Kazemier M · 2 shared papers, 2026 · strength 0.37

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.